Head-to-head evidence
Icotinib vs JS111 AP-L1898
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Icotinib
Developed by Betta Pharmaceuticals Co.
NCT01040780 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with 200 participants assigned to icotinib and 199 to gefitinib, and its primary endpoint was the clinical measure of progression-free survival. Although the reported median favored icotinib, the statistical significance of the primary comparison is not stated, so the result is unclear rather than definitively positive.
Next expected readout: December 2030 · NCT06955325 (registry estimate)
JS111 AP-L1898
Developed by Shanghai Junshi Bioscience
NCT04993391 · Phase 1/2 · status unknown
This is a single-arm, open-label, non-randomized dose-escalation study in 156 people with advanced non-small cell lung cancer, testing five ascending doses with no control group. It is designed primarily to characterize safety, with response rate as a secondary readout, and no results have been posted.
Next expected readout: July 2028 · NCT06940401 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Icotinib's landscape · JS111 AP-L1898's landscape